207940 · KOSPI · ₩SBL · 삼성바이오로직스
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−31.0% from the high
₩1,150,000Today: ₩1,360,000 – ₩1,399,000₩1,987,000
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
Estimated leveraged-ETF rebalance on Oct 28: buy ₩20B at the close (18.3% of 20-day average trading value)
On its 14 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 10.2% of trading value and pointed the same way 9 of 14 times.
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Held by 32 funds.
Estimated from the funds' index or underlying stock.
Futures (2026-11): 1,380,000
Basis +0.58% · implied rate +14.1%
Open interest 7,386 contracts
Options open interest: 1,978 calls, 2,637 puts (put/call 1.33)
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Samsung Biologics (삼성바이오로직스, KRX: 207940) is listed on KOSPI, in the Biotech & Pharma sector. Samsung Biologics is a Korean contract development and manufacturing organization (CDMO) that provides biopharmaceutical contract manufacturing and cell line and process development services to pharmaceutical customers. Its shares closed at ₩1,372,000 on Oct 28, 2026, down 0.15% on the day, giving it a market value of ₩64T.
Samsung Biologics is a Korean contract development and manufacturing organization (CDMO) that provides biopharmaceutical contract manufacturing and cell line and process development services to pharmaceutical customers. Its products are mainly antibody drug products, and its revenue comes largely from Europe and the United States, with production based in Incheon Songdo. The company is expanding into mRNA, ADC, and cell and gene therapy manufacturing, and has launched a Samsung Organoid research service.
Written by AI from the company's latest annual report.
Predicted impact: Medium
Samsung Electronics buys ₩666.2B of new shares, about 1% of market value; ₩5T insurance deal linked.
Predicted impact: Low
Predicted impact: Medium
Final labor talks with possible sequential strikes at a major biotech; strike risk could affect output.
Titles in Korean until English translations are added.
Also known as: Samsung Biologics / 삼성바이오로직스 / 207940 / KRX:207940
Source: KRX statistical information